Table 5.
Results of the scenario 2 and one-way sensitivity analyses (24 weeks)
| Variables | Input values | Incremental costs (US $) | Incremental QALY † | ICER (US $ per QALY gained) |
|---|---|---|---|---|
| Base case |
|
466 |
0.0370 |
12,598 (₩14,198,501/QALY) |
| Cost ratio from Berry 2001 [27] |
|
483 |
0.0370 |
13,065 |
| NYHA class I |
0.049 |
|
|
|
| NYHA class II |
0.049 |
|
|
|
| NYHA class III |
0.120 |
|
|
|
| NYHA class IV |
0.831 |
|
|
|
| FCM price ± 15% (US $) |
136-184 |
370-562 |
0.0370 |
10,009-15,188 |
| Total number of FCM vials ± 1 vial |
3-5 |
306-626 |
0.0370 |
8,282-16,915 |
| CHF medical cost ± 25% (US $) |
1,185-1,975 |
421-512 |
0.0370 |
11370-13,827‡ |
| Effect-onset time |
6th day |
466 |
0.0370 |
12,598 |
| Baseline CHF patient distribution from the expert survey |
|
191 |
0.0370 |
5,165 |
| NYHA class II |
58.3% |
|
|
|
| NYHA class III | 41.7% |
(US $1 = Kor ₩1,127).
CHF, chronic heart failure; FMC, ferric carboxymaltose; ICER, incremental cost-effectiveness ratio; NYHA, New York Heart Association.
† Utility gains in scenario 2 were not changed according to variation of inputs because the utilities were directly obtained from the quality-of-life results at the follow-up periods in the FAIR-HF study.
‡As the CHF medical cost increased, the ICER decreased.